Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.

E Senéterre1, R Weissleder, D Jaramillo

  • 1Department of Radiology, Massachusetts General Hospital Charlestown.

Radiology
|May 1, 1991
PubMed
Summary

This study investigates whether a specific type of iron-based contrast agent can improve magnetic resonance imaging of bone marrow. Researchers tested how these particles affect image signals in animal models and found they help distinguish between healthy marrow and tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Child life intervention successfully decreases anaesthesia requirements in young children undergoing outpatient orthopaedic magnetic resonance imaging (MRI): a retrospective cohort study.

Clinical radiology·2026
Same author

Performance of summary measures of core body temperature in heat-related health outcome regression models.

International journal of biometeorology·2025
Same author

Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Early Outcomes of Preoperative Short Course Radiotherapy With Simultaneous Integrated Boost and Response-adapted Chemotherapy for Advanced Rectal Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Risk factors for 30-day hospital readmission in patients with diabetic foot.

Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons·2024
Same author

Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma.

Hong Kong medical journal = Xianggang yi xue za zhi·2024

Area of Science:

  • Radiology and diagnostic imaging research within USPIO contrast agent development
  • Hematology and musculoskeletal pathology studies

Background:

Clinicians often struggle to distinguish between healthy bone marrow and malignant lesions using standard imaging techniques. This diagnostic limitation hinders the early detection and precise staging of intramedullary tumors. Prior research has shown that conventional contrast agents frequently fail to provide sufficient tissue contrast in these specific regions. No prior work had resolved whether iron-based particles could overcome these inherent signal challenges. That uncertainty drove the investigation into alternative intravenous agents for magnetic resonance applications. It was already known that magnetic properties of iron influence relaxation times during scanning. This gap motivated the exploration of ultrasmall superparamagnetic iron oxide as a potential solution. The current study addresses these persistent difficulties by evaluating a novel contrast preparation in animal models.

Purpose Of The Study:

The aim of this study is to evaluate the potential of an iron-based preparation as an intravenous contrast agent for magnetic resonance imaging of bone marrow. Researchers sought to determine if these particles could improve the visibility of marrow structures and associated pathologies. The study addresses the challenge of distinguishing between healthy tissue and malignant lesions within the skeletal system. By testing various iron concentrations, the team intended to establish an effective dosage for signal modification. The motivation for this work stems from the need for higher sensitivity in detecting intramedullary tumors. Investigators aimed to quantify the reduction in relaxation times to assess the agent's performance. They also sought to define the temporal window during which the contrast effect remains active. This research provides a foundation for understanding how such agents might enhance diagnostic capabilities in clinical settings.

Keywords:
magnetic resonance imagingcontrast agentsintramedullary tumorsrelaxation timesskeletal diagnostics

Frequently Asked Questions

The researchers propose that the agent reduces T1 and T2 relaxation times by approximately 30% to 65% depending on the dosage. This mechanism decreases signal intensity in both red and yellow marrow, which helps clinicians distinguish between healthy tissue and intramedullary tumors.

The study utilizes ultrasmall superparamagnetic iron oxide particles, which are iron-based contrast agents. These particles are administered intravenously to alter the magnetic environment of the marrow, allowing for improved visualization compared to standard imaging techniques.

Gradient echo pulse sequences are necessary because they produce the most marked decrease in signal intensity. This technical requirement ensures that the contrast between tumor deposits and normal marrow is maximized for accurate diagnostic interpretation.

Related Experiment Videos

Main Methods:

Review approach involved evaluating the agent in rat and rabbit models to assess imaging efficacy. The researchers administered iron doses ranging from 40 to 160 micromoles per kilogram body weight intravenously. They monitored T1 and T2 relaxation times to quantify the impact of the particles on magnetic resonance signals. The team performed imaging sessions at various intervals to track signal intensity changes over time. They specifically utilized gradient echo pulse sequences to optimize the contrast between different tissue types. The study also incorporated an animal model of intramedullary tumors to test diagnostic utility. Investigators compared the signal characteristics of malignant lesions against those of healthy red and yellow marrow. This systematic process allowed for the characterization of the agent's behavior within the skeletal environment.

Main Results:

Key findings from the literature show that T1 and T2 relaxation times decreased by approximately 30%, 50%, and 65% following specific iron dosages. The maximum reduction in marrow relaxation times occurred within the first 24 hours after injection. Signal intensity in both red and yellow marrow decreased significantly, particularly when using gradient echo pulse sequences. The researchers observed that relaxation times slowly returned to normal levels within 7 days. The animal model demonstrated that the agent enables clear differentiation between intramedullary tumors and normal red marrow. This enhancement facilitates the detection of smaller tumors that would otherwise be difficult to identify. The data confirm that the agent allows for the separation of tumor deposits from islands of hyperplastic marrow. These results highlight the potential of the preparation to improve diagnostic clarity in bone marrow imaging.

Conclusions:

The authors conclude that the iron-based preparation effectively alters relaxation times in both red and yellow marrow. Synthesis and implications suggest that this agent enhances the visibility of small intramedullary tumors during scanning. The researchers propose that the observed signal reduction allows for clearer differentiation between malignant deposits and healthy marrow islands. Their data indicate that gradient echo pulse sequences provide the most significant contrast improvements for this application. The findings imply that intravenous administration offers a viable pathway for improving diagnostic accuracy in bone marrow assessments. The study demonstrates that these particles return to baseline levels within one week, suggesting a temporary effect. The authors highlight that this approach facilitates the identification of smaller lesions that might otherwise remain undetected. These results support the continued investigation of such agents to refine clinical imaging protocols for marrow-related pathologies.

The researchers use animal models, specifically rats and rabbits, to evaluate the agent. This data type allows for the observation of signal changes in both red and yellow marrow over a seven-day period following administration.

The measurement involves tracking the relaxation times of marrow over time. The authors observed that the maximum decrease occurs within 24 hours, with a gradual return to baseline levels by the seventh day post-injection.

The authors propose that this agent improves the detection of small tumors. They claim it allows for the differentiation of tumor deposits from islands of hyperplastic or normal red marrow, which is a significant clinical advantage.